The primary goal of therapy for chronic hepatitis B (CHB) is to prevent liver disease progression. Hepatitis B surface antigen (HBsAg) seroclearance or seroconversion is regarded as an optimal endpoint to discontinue treatment. However, HBsAg seroclearance occurs very rarely with nucleos(t)ide analog (NUC) treatment, and long-term, almost indefinite, NUC treatment is required for the majority of patients. In patients with drug-resistant hepatitis B virus (HBV), a combination of tenofovir disoproxil fumarate (TDF) and entecavir (ETV), which is currently regarded as the strongest combination therapy against HBV, would be potentially safe to prevent the emergence of additional HBV resistance mutations. However, long-term tolerance data are lacking, and cost may be an issue for combination therapies. Several recent, well-designed, randomized controlled trials have shown that TDF monotherapy provides similar antiviral efficacy compared with the combination of TDF and ETV. Furthermore, no additional HBV resistance mutations emerged during TDF monotherapy for up to 96 weeks. Considering a comparable antiviral efficacy, extremely low risk of TDF-resistance, lower cost, and better safety potential, TDF monotherapy would be a reasonable choice for the treatment of drug-resistant patients with CHB. (Gut Liver 2017; 11:189-195) 
INTRODUCTION
High serum hepatitis B virus (HBV) DNA levels are an independent risk factor for disease progression to cirrhosis and hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB).
1,2 By contrast, reducing HBV DNA concentrations to very low or undetectable levels through long-term nucleos(t)ide analogue (NUC) therapy is associated with reduced risk of mortality and/or HCC. [3] [4] [5] [6] [7] [8] [9] [10] [11] Over the past two decades, treatment of CHB has greatly improved with the availability of NUCs, including lamivudine (LAM), adefovir (ADV), entecavir (ETV), telbivudine, and tenofovir, which target particular sites of viral polymerases. [12] [13] [14] Particularly, with the availability of potent NUCs, such as tenofovir disoproxil fumarate (TDF) and ETV, suppression of serum HBV DNA to levels undetectable by polymerase chain reaction assays is achievable in most NUC treatment-naïve patients in the absence of drug-resistant HBV mutants ( Fig. 1) . 15, 16 However, many patients worldwide have developed drug-resistance from the widespread use of less potent NUCs, such as LAM or ADV, which have a low genetic barrier to resistance. Patients with persistent drug-resistant HBV viremia are more likely to suffer hepatitis flares, disease progression, and to die than those without drug-resistant HBV. 
MECHANISM OF ANTIVIRAL DRUG RESISTANCE
Nucleoside-and nucleotide-analogues selectively target HBV DNA polymerase, resulting in premature chain termination of viral replication. Drug-resistant strains of HBV have signature mutations in the reverse transcriptase domains of the viral polymerase gene (Table 1) . Resistance mutations alter the interaction between HBV polymerase and drug, which interfere the inhibitory effect of drug on viral polymerase. After emergence of primary resistance mutations, compensatory mutations that restore replication capacity may arise (Fig. 2) , as well as secondary resistance mutations that increase drug resistance when they accumulate on the same viral genome.
Once antiviral-resistant HBV mutants have been selected, they are persistently retained in the virus population even if treatment is stopped, and exerts cross-resistance to the next sequential monotherapy (Fig. 2) . 14, 17, 18 For example, ADV-resistant mutations emerge more frequently during ADV monotherapy in LAM-resistant than in treatment-naïve patients. [19] [20] [21] The rate of ETV resistance increases up to 51% after 5 years of ETV treatment in patients with LAM-resistant HBV, which is in striking contrast to a 1.2% resistance rate in NUC-naïve patients. 22, 23 Thus, combination therapy with a nucleoside analogue (LAM, telbivudine, or ETV) and a nucleotide analogue (ADV or TDF) has generally been recommended for the treatment of patients harboring drug-resistant HBV. 14, [24] [25] [26] However, several recent studies including ours have suggested that TDF monotherapy is efficacious in patients with LAM-resistant, ETV-resistant, or ADV-resistant HBV.
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MANAGEMENT OF RESISTANCE TO LAMIVUDINE
For LAM-resistant patients, a combination of ADV and LAM showed no greater antiviral efficacy than ADV monotherapy. Nonetheless, ADV and LAM combination therapy had been recommended for these patients to prevent additional emergence of ADV-resistant HBV mutants. 14, 20, 24, 25, [34] [35] [36] However, the situation is clearly different if TDF, that has about 30 times higher anti-HBV potency than ADV, is used instead of ADV. Treatment responses to TDF and LAM combination therapy would likely be mediated by TDF alone, since LAM may have no or minimal antiviral efficacy in the presence of LAM-resistant HBV mutants. With this combination, continued LAM treatment would likely only help prevent the development of TDF-resistance mutations, rather than increasing antiviral potency. Therefore, if there is minimal risk of TDF-resistance, 16, 37 the addition of LAM to TDF would theoretically provide little benefit. The hypothesis was actually proven by a recent randomized double-blind controlled trial. 29 The study showed that TDF monotherapy was highly efficacious in patients with LAM-resistant HBV, which was comparable to the combination of TDF and emtricitabine, without emergence of additional resistance mutations to TDF throughout 96 weeks of treatment (Fig. 3) . 29, 37 Entricitabine is an unapproved nucleoside analogue which has very similar anti-HBV potency and barrier to resistance development as LAM. Thus, the study results indicate that adding LAM to TDF would not provide additional antiviral benefit, and that TDF monotherapy is safe and efficacious to patients with LAM-resistant HBV.
MANAGEMENT OF RESISTANCE TO LAM AND ETV
In patients with pre-existing LAM-resistance, the rate of ETV resistance increases up to 51% after 5 years of ETV treatment, which is in striking contrast to a 1.2% resistance rate in NUCnaïve patients. 22, 23 In addition, ETV monotherapy was suboptimal in suppressing HBV replication in patients with LAMresistant HBV, with an unacceptably low virologic response rate (22%) seen at 12 months. 38, 39 This difference is because the ETV resistance barrier is lowered by the initial selection of the LAM-resistant HBV mutation, rtM204V/I. 40 In vitro studies have
shown that susceptibility to ETV is decreases by 10-to 250-fold when one of the ETV resistance-associated substitutions at rtT184, rtS202, or rtM250 is present in combination with rtM204V/I, and by >500-fold when two or more of these mutations are present. 22, 40 In vitro studies suggest that ETV-resistant HBV mutants are susceptible to TDF. 17, 41 These in vitro studies showed that HBV strains harboring the ETV resistance-associated substitutions, rtM204V/I, rtT184, rtS202, and/or rtM250, exhibit no crossresistance to tenofovir. 17, 41 Several case reports and retrospective cohort studies also showed the clinical efficacy of TDF in ETVresistant or ETV-refractory patients. [42] [43] [44] In our recent multicenter randomized trial, patients who had HBV with ETV resistance-associated mutations and serum HBV DNA concentrations >60 IU/mL were randomized to receive TDF (300 mg/day) monotherapy (n=45) or TDF and ETV (1 mg/day) combination therapy (n=45). At week 48, the proportion of patients with HBV DNA <15 IU/mL, the primary efficacy endpoint, was not significantly different between the TDF and TDF+ETV groups (71% vs 73%, p=0.81). The proportion of patients who achieved HBV DNA levels <60 IU/mL at week 48 was 82% and 89% for the TDF and TDF+ETV groups, respectively (p=0.55) (Fig. 4) . The mean change in HBV DNA levels from baseline was not significantly different between groups (-3.65 log 10 IU/ mL vs -3.77 log 10 IU/mL, p=0.69). Virologic breakthrough occurred in one patient on TDF, which was attributed to poor drug adherence. At week 48, six and three patients in the TDF and TDF+ETV groups, respectively, retained their baseline resistance mutations (p>0.99). None developed additional resistance mutations. Safety profiles were comparable in the two groups. The rate of virologic response by TDF monotherapy in our study was similar with that of a recent single arm trial with TDF+ETV in CHB patients with previous NUC treatment failure (85% had HBV DNA <50 IU/mL at week 96). 45 These results support the view that TDF monotherapy may be a treatment option for patients with ETV-resistant HBV.
MANAGEMENT OF RESISTANCE TO LAM AND ADV
In vitro clonal analyses showed that multidrug-resistance mutations usually reside in the same viral genome, 18, 46 and antiviral sensitivities revealed that replicating clones with LAMand ADV-associated mutations had >50-fold reduced susceptibility to combination of LAM and ADV. 47, 48 In fact, our previous cohort study demonstrated that, in patients with HBV resistant to LAM and ADV, combination therapy with these two drugs was not effective and was even inferior to ETV monotherapy in suppressing HBV DNA. 49 However, the response to ETV monotherapy was not optimal. We demonstrated that ETV was far less effective in patients refractory to both LAM and ADV than in those with LAM mono-resistance. 50 In vitro studies have shown that HBV strains expressing the ADV resistance-associated substitutions, rtA181T/V and/or rtN236T, demonstrate reduced susceptibility to tenofovir, ranging from 2.9-to 10-fold of that of the wild-type virus. 46, [51] [52] [53] Several cohort studies also showed reduced TDF efficacy in patients with ADV-resistant HBV. 30, 54 An European cohort study showed that, the probability of achieving HBV DNA levels below 400 copies/mL was significantly lower with TDF monotherapy in patients with ADV-resistant HBV and high viral load (>10 7 copies/mL) at baseline compared with those without ADV-resistant HBV. 54 Another cohort study also showed that the efficacy of TDF was lower in patients with ADV-resistant HBV than in treatment-naïve patients, especially when they had previously failed to respond to both LAM and ADV. 30 On the other hand, a combination of TDF and ETV, which is currently regarded as the strongest combination therapy against HBV, induced a virologic response in up to 90% of patients after a median 6 months of treatment regardless of preexisting ADVor ETV-resistance. 55 However, whether a combination of TDF and ETV exerts better antiviral efficacy than TDF monotherapy in patients with multidrug-resistant HBV could not be identified by these single arm studies.
We recently performed a multicenter trial, in which, patients who had ADV-resistant HBV with serum HBV DNA levels >60 IU/mL were randomized to receive TDF (300 mg/day) monotherapy (n=50) or TDF and ETV (1 mg/day) combination therapy (TDF/ETV, n=52) for 48 weeks. All patients had ADV-resistant HBV mutations; rtA181V/T and/or rtN236T. The proportion of patients with HBV DNA <15 IU/mL was not significantly different between the TDF-TDF and TDF/ETV-TDF groups at week 48 (62% vs 63.5%, p=0.88) and at week 96 (64% vs 63.5%, p=0.96). The proportion of patients who achieved HBV DNA levels <60 IU/mL at week 48 was 74% and 78.8% for the TDF-TDF and TDF/ETV-TDF groups, respectively (p=0.56) (Fig. 5) . Virologic breakthrough occurred in one patient on TDF-TDF and two patients on TDF/ETV-TDF over 96 weeks; all were attributed to poor drug adherence. At week 96, five and two patients in the TDF-TDF and TDF/ETV-TDF groups, respectively, retained some of their baseline resistance mutations (p=0.44). None developed additional resistance mutations. Safety profiles were comparable in the two groups. The results suggest that TDF monotherapy may be a treatment option for patients with ADV-resistant HBV. However, in a subgroup of patients who had double ADV-resistance mutations, i.e., both rtA181T/V and rtN236T, the decrease in serum HBV DNA levels tended to be less in the TDF group than in the TDF/ETV-TDF group. Thus, TDF plus ETV combination therapy might be more beneficial than TDF monotherapy in patients who had double ADV-resistance mutations (both rtA181T/V and rtN236T).
CONCLUSIONS
The primary goal of therapy for CHB is to prevent liver disease progression, and seroclearance or seroconversion of hepatitis B surface antigen (HBsAg) is regarded as an optimal endpoint of treatment. 56 However, HBsAg seroclearance occurs very rarely with NUC treatment. 56 Long-term HBV DNA and HBsAg level kinetics in patients with CHB treated with potent NUCs showed that HBsAg clearance is unlikely to occur during the patient's lifetime, even if HBV replication is well controlled. 57 Thus, long-term, almost indefinite, NUC treatment is required for the majority of patients.
In patients with drug-resistant HBV, a combination of TDF and ETV would be potentially safer to prevent the emergence of resistance to TDF. 58 However, long-term tolerance data are lacking and cost may be an issue for this combination. Considering a comparable antiviral efficacy, extremely low risk of TDFresistance, lower cost, and potentially better safety profile, TDF monotherapy would be a reasonable option for the treatment of ETV-resistant patients. In fact, TDF monotherapy is now being incorporated as a primary recommendation for the treatment of patients with drug-resistant HBV in many recent practice guidelines (Table 2) . 24, [59] [60] [61] [62] However, the rates of virologic response in multidrug-resistant patients seem to be lower compared to those reported in previous clinical trials of TDF in treatment-naïve, LAM-resistant, or ADV-refractory patients. 27, 29, 63 Because the combination of TDF and ETV does not seem to further increase the rate of virologic response, a more potent antiviral agent may be required for patients with HBV mutants resistant to multiple drugs including ADV.
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